{"prompt": "['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', 'As-needed supplemental oxygen use provided it is <3L/min flow at rest at', 'screening. Patients may adjust oxygen levels as needed during the study.', 'Pulmonary rehabilitation program in maintenance phase', 'Smoking cessation treatment, including a stable regimen of nicotine replacement', 'Use of positive airway pressure/non-invasive ventilation for sleep apnea/sleep', 'disordered breathing (e.g. CPAP, BiPAP)', 'Localized corticosteroid injections (e.g., intra-articular and epidural)', 'Oral muscarinic antagonists for the treatment of overactive bladder are permitted', 'but should be used with caution as they may exacerbate medical conditions that', 'are contraindicated for anticholinergics (e.g., narrow angle glaucoma and bladder', 'outflow obstruction)', 'Immunotherapy injections', 'Topical or ophthalmic corticosteroids', 'Over-the counter (OTC) cough suppressants', 'Tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs). Administer', 'with caution as they may potentiate the effect of beta-agonists on the vascular', 'system', 'Diuretics. Caution is advised in the co-administration of beta agonists with non-', 'potassium sparing diuretics', 'Allergy vaccination', 'All medications for other disorders as long as the dose remains constant whenever', 'possible and their use would not be expected to affect lung function', '6.11.2.', 'Prohibited Medications and Non-Drug Therapies', 'Use of the medications listed in Table 6 is not permitted during the study', '40']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Table 6', 'Prohibited Medications and Non-Drug Therapies', 'Medication', 'Depot corticosteroids', 'Systemic, oral or parenteral corticosteroids\u00b9', 'Inhaled corticosteroids (ICS)2', 'Antibiotics >14 days', 'LABA/ICS combination products', 'PDE4 inhibitor (e.g. roflumilast)', 'Inhaled long acting betaz-agonists (LABA, e.g. salmeterol, formoterol, indacaterol, vilanterol)', 'Long-acting muscarinic antagonists (LAMA, e.g. tiotropium, aclidinium, glycopyrronium, umeclidinium\u00b3', 'LAMA/LABA combination products except for study drugs', 'Theophyllines', 'Oral beta2-agonists', 'Inhaled short acting beta2-agonists4', 'Inhaled short-acting anticholinergics', 'Inhaled short-acting anticholinergic/short-acting betaz-agonist combination products', 'Any other investigational medication', '1', 'Except for the treatment of COPD exacerbations during the study. Localized corticosteroid injections (e.g.,', 'intra-articular and epidural) are permitted.', '2', \"Except if during the study use of ICS is deemed necessary for the treatment of subjects' exacerbation.\", '3', 'Expect for study drug', '4', 'Use of study provided albuterol/salbutamol is permitted during the study, except in the 4-hour period prior to', 'spirometry testing.', 'The following medications or treatments are also not allowed during the study:', 'Use of long-term oxygen therapy (LTOT) described as resting oxygen therapy', '>3L/min only at screening. Oxygen may be titrated to any level deemed necessary', 'during the study.', 'Regular (prescribed for daily/regular use, not for as-needed use) therapy with', 'albuterol/salbutamol', 'Initiation of pulmonary rehabilitation during the study.', '7.', 'STUDY ASSESSMENTS AND PROCEDURES', 'Protocol waivers or exemptions are not allowed with the exception of immediate safety', 'concerns. Therefore, adherence to the study design requirements, including those', 'specified in the Time and Events Table Section 7.1, are essential and required for study', 'conduct.', 'This section lists the procedures and parameters of each planned study assessment. The', 'exact timing of each assessment is listed in the Time and Events Table Section 7.1', '41']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_0', '201749', '7.1.', 'Time and Events Table', 'Blinded Treatment', 'Pre-', 'Screen/', 'Rando-', 'Telephone Follow up', 'screen1', 'Run-in', 'mization', 'EW', 'contact', 'Visit', '0', '1', '2', '3', '4', '5', 'Visit 2', '6', 'Week', '-6 to -4', '-4', '0', '4', '12', '24', '42 1-7/+2', '28 -7/+2', '1-7/+2', '28 -7/+2', '84 -7/+2', '168 -7/+2', '7+3 days after V5 or', 'days', 'days prior', 'days', 'days', 'days', 'days', 'EW Visit', 'prior', 'Visit 2', 'Day', 'Visit 1', 'Screen/Baseline', 'Written informed consent', 'X', 'Demography', 'X', 'Medical/COPD history', 'X', 'Smoking history/status', 'X', 'Smoking cessation counselling', 'X', 'Concomitant medication assessment', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Height and weight', 'X', 'Cardiovascular History/family history of premature CV', 'X', 'disease])', 'Screening spirometry (including post bronchodilator', 'X', 'testing)\u00b3', 'CAT questionnaire', 'X', 'X', 'Verify Inclusion/Exclusion Criteria', 'X', 'Training on use of inhalers', 'X', 'X', 'Training on use of eDiary and eMDI', 'X', 'X', 'Verify randomization Criteria', 'X', 'Register Visit in InForm', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Register Visit in RAMOS NG', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '42']\n\n###\n\n", "completion": "END"}